Smith & Nephew closed its deal to add Fort Saskatchewan, Canada-based Nucryst's technology to its wound care portfolio.
The wound management division of Smith & Nephew (NYSE:SNN) closed its $21 million deal for Nucryst Pharmaceuticals Corp. (NASDAQ:NCST; TSX:NCS).
Smith & Nephew will use the Fort Saskatchewan, Canada-based company's nanocrystalline silver technology intellectual property in its Acticoat wound dressing, the second-largest brand in its wound management portfolio, according to a press release.
Smith & Nephew will absorb all the manufacturing assets from Nucryst’s Fort Saskatchewan, Canada operations and its entire intellectual property estate, according to the release.
The wound management division, which houses its U.S. headquarters in St. Petersburg, Fla., announced the deal in November.
Warren Watson, a 30-year Medtronic Inc. employee with family connections to founder Earl Bakken, is...
Quidel Corp. wins Food & Drug Administration 510(k) clearance for its chorionic gonadotropin-...
Ann Arbor, Mich.-based HistoSonics Inc. snags former Food & Drug Administration commissioner Dr....
The Food & Drug Administration releases a list of the medical devices it granted 510(k) clearance...
A federal grand jury indicts former Spectranetics CEO John Schulte, two other executives and a...